Hypoxia-inducible factor HIF-1α: pharmacogenetic perspective for bevacizumab therapy individualization

被引：0
|
作者：
Tauser, Roxana-Georgiana [1 ]
Zugun-Eloae, Florin [2 ]
Jitaru, Daniela [3 ]
Carasevici, Eugen [2 ]
机构：
[1] Gr T Popa Univ Med & Pharm Iasi, Dept Med Chem, Sch Pharm, Iasi 700115, Romania
[2] Gr T Popa Univ Med & Pharm Iasi, Sch Med, Dept Immunol, Iasi 700115, Romania
[3] St Spiridon Univ Emmergency Hosp Iasi, Iasi, Romania
来源：
REVISTA ROMANA DE MEDICINA DE LABORATOR | 2009年 / 16卷 / 03期
关键词：
pharmacogenetics; bevacizumab; hypoxia inducible factor; cancer; CIRCULATING ENDOTHELIAL-CELLS; METASTATIC COLORECTAL-CANCER; BREAST-CANCER; POLYMORPHISMS; ANGIOGENESIS; CHALLENGES; FLUOROURACIL; CHEMOTHERAPY; LEUCOVORIN; GENE;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Pharmacogenetics of innovative angiogenic-targeted monoclonal antibody therapy, yet in its infancy, will be crucial in treatment individualization according to the genetic profile of each patient and molecular features of tumors. Bevacizumab (Avastin) specifically targets the key promotor of angiogenesis - vascular endothelial growth factor (VEGF), whose transcription is critically regulated by hypoxia-inducible factor HIF-1 alpha. The present paper points out the clinical relevance of HIF-1 alpha common genetic polymorphisms to the inter-individual variability in response to anti-VEGF-targeted monoclonal antibody therapeutic regimens, with special reference to colorectal cancer.
引用
收藏
页码：7 / 12
页数：6
相关论文
共 50 条
  • [21] Anti-angiogenic therapy in combination with hypoxia-inducible factor-1α (HIF-1α) modulation
    Falchook, G. S.
    Jackson, E. F.
    Wheler, J. J.
    Moulder, S. L.
    Hong, D. S.
    Naing, A.
    Tannir, N. M.
    Lawhorn, K. N.
    Ng, C. S.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Hypoxia-inducible factor-1α ( HIF-1α) modulation in combination with anti-angiogenic therapy
    Falchook, G. S.
    Wheler, J. J.
    Tannir, N. M.
    Naing, A.
    Jackson, E.
    Hong, D.
    Lawhorn, K. N.
    Ng, C.
    Amin, H.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Targeting hypoxia inducible factor 1 (HIF-1) for cancer therapy
    Melillo, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 23 - 23
  • [24] Hypoxia-inducible factor (HIF-1)α:: its protein stability and biological functions
    Lee, JW
    Bae, SH
    Jeong, JW
    Kim, SH
    Kim, KW
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2004, 36 (01): : 1 - 12
  • [25] The HIF-1 Hypoxia-Inducible Factor Modulates Lifespan in C. elegans
    Zhang, Yi
    Shao, Zhiyong
    Zhai, Zhiwei
    Shen, Chuan
    Powell-Coffman, Jo Anne
    PLOS ONE, 2009, 4 (07):
  • [26] Hypoxia-inducible factor-1 (HIF-1):: A novel transcription factor in immune reactions
    Hellwig-Bürgel, T
    Stiehl, DP
    Wagner, AE
    Metzen, E
    Jelkmann, W
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2005, 25 (06): : 297 - 310
  • [27] Hypoxia-Inducible Factor-1α (HIF-1α) as a Factor to Predict the Prognosis of Spinal Chordoma
    He, Guanping
    Liu, Xiaoguang
    SPINE, 2024, 49 (09) : 661 - 669
  • [28] Hypoxia-inducible factor (HIF-1)α: its protein stability and biological functions
    Ji-Won Lee
    Seong-Hui Bae
    Joo-Won Jeong
    Se-Hee Kim
    Kyu-Won Kim
    Experimental & Molecular Medicine, 2004, 36 : 1 - 12
  • [29] Mitochondria and the hypoxia-inducible factor 1 (HIF-1): regulation of HIF-1 is independent of a functional mitochondrial respiratory chain
    Doege, K
    Jelkmann, W
    Metzen, E
    FEBS JOURNAL, 2005, 272 : 153 - 153
  • [30] Temperature regulates hypoxia-inducible factor-1 (HIF-1) in crucian carp
    Rissanen, E.
    Numminen, H.
    Sollid, J.
    Nilsson, G. E.
    Nikinmaa, M.
    COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY, 2005, 141 (03): : S186 - S186
12345